Sexual health
Bremelanotide / PT-141
Editorial audit: October 15, 2026 · draft; scientific, medical and translation review pending
01What is reported
PT-141 is described for sexual desire and performance across broad populations, including uses outside the studied product indication.
02Proposed rationale
Melanocortin signaling is offered as the explanation. Desire, arousal and performance are distinct endpoints, not a single universal response.
03What the research shows
The US Vyleesi label concerns a specific form of acquired generalized low desire in premenopausal women. That is not approval for men or every sexual complaint.
04Limits and unknowns
Blood-pressure effects and labeled cardiovascular restrictions are material. A positive result for the authorized product does not establish a community stack or another preparation.
05Questions to ask about the product
Confirm product, indication, population and relevant label restrictions before interpreting any claim.
06Open research question
Which outcomes do reports actually describe, and do they separate desire, function, adverse effects and concomitant medicines?
Primary and regulatory references
- 1.